Non-alcoholic fatty liver disease: A patient guideline

S.M. Francque*, G. Marchesini, A. Kautz, M. Walmsley, R. Dorner, J.V. Lazarus, S. Zelber-Sagi, K. Hallsworth, L. Busetto, G. Fruhbeck, D. Dicker, E. Woodward, M. Korenjak, J. Willemse, G.H. Koek, S. Vinker, M. Ungan, J.M. Mendive, C. Lionis

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

20 Citations (Web of Science)

Abstract

This patient guideline is intended for all patients at risk of or living with non-alcoholic fatty liver disease (NAFLD). NAFLD is the most frequent chronic liver disease worldwide and comes with a high disease burden. Yet, there is a lot of unawareness. Furthermore, many aspects of the disease are still to be unravelled, which has an important impact on the information that is given (or not) to patients. Its management requires a close interaction between patients and their many healthcare providers. It is important for patients to develop a full understanding of NAFLD in order to enable them to take an active role in their disease management. This guide summarises the current knowledge relevant to NAFLD and its management. It has been developed by patients, patient representatives, clinicians and scientists and is based on current scientific recommendations, intended to support patients in making informed decisions. (C) 2021 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).
Original languageEnglish
Article number100322
Number of pages39
JournalJHEP Reports
Volume3
Issue number5
DOIs
Publication statusPublished - 1 Oct 2021

Keywords

  • LIFE-STYLE MODIFICATION
  • SERUM ALANINE AMINOTRANSFERASE
  • PLACEBO-CONTROLLED TRIAL
  • Y GASTRIC BYPASS
  • QUALITY-OF-LIFE
  • BARIATRIC SURGERY
  • PHYSICAL-ACTIVITY
  • HEPATOCELLULAR-CARCINOMA
  • HEPATIC STEATOSIS
  • UNITED-STATES

Cite this